Department of Orthopaedic Surgery, Yonsei University College of Medicine, Seoul, Korea.
Foot Ankle Int. 2013 Oct;34(10):1389-94. doi: 10.1177/1071100713488091. Epub 2013 Apr 25.
The purpose of this study was to evaluate the clinical outcomes and usefulness of OK-432 (Picibanil) sclerotherapy as a new option in the conservative treatment of patients with malleolar bursitis of the ankle.
Retrospectively, we reviewed a total of 20 consecutive patients (20 feet) in whom OK-432 sclerotherapy had been performed between March 2009 and June 2010. After aspiration of fluid in the malleolar bursal sac, 0.05 mg of OK-432 was injected into the malleolar bursal sac. We evaluated the clinical outcomes and side effects at the following time points: 2 weeks, 1 month, 3 months, 6 months, and 1 year after OK-432 sclerotherapy. The responses to the treatment were assessed according to the degree of fluctuation, shrinkage of the bursal sac, and soft tissue swelling.
Complete resolution was observed in 19 patients (95%) after the first or second application of OK-432 sclerotherapy, and a partial response was observed in 1 patient (5%) after a second application of OK-432 sclerotherapy. The physical component scores of SF-36 improved from 70.0 ± 6.8 to 76.5 ± 7.3 at the last follow-up (P = .0002).
OK-432 sclerotherapy was a useful procedure for patients not responding to the usual conservative treatment of malleolar bursitis of the ankle.
Level IV, retrospective case series.
本研究旨在评估 OK-432（Picibanil）硬化疗法作为一种新的保守治疗踝关节跗骨滑囊炎的选择的临床疗效和实用性。
回顾性分析 2009 年 3 月至 2010 年 6 月期间接受 OK-432 硬化治疗的 20 例（20 足）连续患者。在抽吸跗骨滑囊积液后，将 0.05mg 的 OK-432 注入跗骨滑囊。我们在 OK-432 硬化治疗后 2 周、1 个月、3 个月、6 个月和 1 年评估临床疗效和不良反应。根据波动程度、滑囊收缩和软组织肿胀评估治疗反应。
19 例患者（95%）在第一次或第二次 OK-432 硬化治疗后完全缓解，1 例患者（5%）在第二次 OK-432 硬化治疗后部分缓解。SF-36 生理成分评分从治疗前的 70.0±6.8 提高到最后随访时的 76.5±7.3（P=0.0002）。
OK-432 硬化治疗对常规保守治疗踝关节跗骨滑囊炎无效的患者是一种有用的治疗方法。
IV 级，回顾性病例系列。
